ClinicalTrials.gg
CompletedNCT02263911Updated Jun 6, 2017Results posted

A Study of Baricitinib in Healthy Japanese Participants

A Phase 1 interventional study of Baricitinib in Healthy Participants, sponsored by Eli Lilly and Company. Completed at 1 site in Japan. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to understand the relationship of 3 different dosage forms of baricitinib. This study will also explore the effect of food on how the body absorbs baricitinib. This study will last about 5 weeks, not including screening. Screening is required within 28 days prior to the date of first dosing.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy Japanese male and female (women not of or after menopause), as determined by medical history and physical examination
  • Have a (BMI) of 18.5 to 29.9 kilogram per square meter (kg/m\^2)
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

Exclusion criteria

Exclusion Criteria:

  • Have an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have an abnormal blood pressure as determined by the investigator
  • Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • Are women who are pregnant or lactating
  • Have used or intend to use over-the-counter or prescription medication, including herbal medications, within 14 days prior to dosing and during the study.
  • Have donated blood of more than 400 milliliter (mL) in the last 12 weeks (males) or in the last 16 weeks (females), or any blood donation (including apheresis) within the last 4 weeks, or total volume of blood donation within 12 months is 1200 mL (males) or 800 mL (females) at screening.
  • Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), or are unwilling to abide by alcohol restrictions
  • Are participants who currently smoke more than 10 cigarettes per day (or equivalent in tobacco or nicotine products) or are unwilling to abide by smoking restrictions
  • Have a current or recent history of a bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection
  • Have an (ANC) less than 2000 cells/microliter (µL)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Baricitinib Test Treatment 1 (T1)

    Single oral dose of 2 × 4 milligram (mg) baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.

    Drug: Baricitinib

  • Experimental
    Baricitinib Reference Treatment 1 (R1)

    Single oral dose of 1 × 8 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.

    Drug: Baricitinib

  • Experimental
    Baricitinib Test Treatment 2 (T2)

    Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.

    Drug: Baricitinib

  • Experimental
    Baricitinib Reference Treatment 2 (R2)

    Single oral dose of 1 × 4 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.

    Drug: Baricitinib

  • Experimental
    Baricitinib Test Treatment 2 with Meal (T2F)

    Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet after food intake on Day 1 in one of five periods.

    Drug: Baricitinib

Interventions

  • Administered orally

    Also known as: LY3009104

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Baricitinib

    Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, and 48 Hours Post-dose

  2. PK: Area Under the Concentration Versus Time Curve From Zero to Last Measurable Concentration (AUC[0-tlast]) of Baricitinib

    Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, and 48 Hours Post-dose

  3. PK: Maximum Concentration (Cmax) of Baricitinib

    Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, and 48 Hours Post-dose

07

Results

Posted Apr 21, 2017

Participant flow

Period 1
Participant flow — Period 1
MilestoneBaricitinib Dosing Sequence 1Baricitinib Dosing Sequence 2Baricitinib Dosing Sequence 3Baricitinib Dosing Sequence 4
Started4444
Completed4444
Not completed0000
Period 1 Washout
Participant flow — Period 1 Washout
MilestoneBaricitinib Dosing Sequence 1Baricitinib Dosing Sequence 2Baricitinib Dosing Sequence 3Baricitinib Dosing Sequence 4
Started4444
Completed4444
Not completed0000
Period 2
Participant flow — Period 2
MilestoneBaricitinib Dosing Sequence 1Baricitinib Dosing Sequence 2Baricitinib Dosing Sequence 3Baricitinib Dosing Sequence 4
Started4444
Completed4444
Not completed0000
Period 2 Washout
Participant flow — Period 2 Washout
MilestoneBaricitinib Dosing Sequence 1Baricitinib Dosing Sequence 2Baricitinib Dosing Sequence 3Baricitinib Dosing Sequence 4
Started4444
Completed4444
Not completed0000
Period 3
Participant flow — Period 3
MilestoneBaricitinib Dosing Sequence 1Baricitinib Dosing Sequence 2Baricitinib Dosing Sequence 3Baricitinib Dosing Sequence 4
Started4444
Completed4444
Not completed0000
Period 3 Washout
Participant flow — Period 3 Washout
MilestoneBaricitinib Dosing Sequence 1Baricitinib Dosing Sequence 2Baricitinib Dosing Sequence 3Baricitinib Dosing Sequence 4
Started4444
Completed4444
Not completed0000
Period 4
Participant flow — Period 4
MilestoneBaricitinib Dosing Sequence 1Baricitinib Dosing Sequence 2Baricitinib Dosing Sequence 3Baricitinib Dosing Sequence 4
Started4444
Completed4444
Not completed0000
Period 4 Washout
Participant flow — Period 4 Washout
MilestoneBaricitinib Dosing Sequence 1Baricitinib Dosing Sequence 2Baricitinib Dosing Sequence 3Baricitinib Dosing Sequence 4
Started4444
Completed4444
Not completed0000
Period 5
Participant flow — Period 5
MilestoneBaricitinib Dosing Sequence 1Baricitinib Dosing Sequence 2Baricitinib Dosing Sequence 3Baricitinib Dosing Sequence 4
Started4444
Completed4444
Not completed0000

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Baricitinib
Time frame:
Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, and 48 Hours Post-dose
Reported as:
Geometric mean · nanogram*hour/milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Baricitinib
nanogram*hour/milliliter (ng*h/mL)Baricitinib T1Baricitinib R1Baricitinib T2Baricitinib R2Baricitinib T2F
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Baricitinib626 ± 19584 ± 20297 ± 17301 ± 17254 ± 14
PrimaryPK: Area Under the Concentration Versus Time Curve From Zero to Last Measurable Concentration (AUC[0-tlast]) of Baricitinib
Time frame:
Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, and 48 Hours Post-dose
Reported as:
Geometric mean · ng*h/mL
PK: Area Under the Concentration Versus Time Curve From Zero to Last Measurable Concentration (AUC[0-tlast]) of Baricitinib
ng*h/mLBaricitinib T1Baricitinib R1Baricitinib T2Baricitinib R2Baricitinib T2F
PK: Area Under the Concentration Versus Time Curve From Zero to Last Measurable Concentration (AUC[0-tlast]) of Baricitinib622 ± 19580 ± 20294 ± 17298 ± 17251 ± 14
PrimaryPK: Maximum Concentration (Cmax) of Baricitinib
Time frame:
Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, and 48 Hours Post-dose
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
PK: Maximum Concentration (Cmax) of Baricitinib
nanogram/milliliter (ng/mL)Baricitinib T1Baricitinib R1Baricitinib T2Baricitinib R2Baricitinib T2F
PK: Maximum Concentration (Cmax) of Baricitinib107 ± 29103 ± 2750.7 ± 2553.1 ± 1845.1 ± 31

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baricitinib T1—0/16 (0%)0/16 (0%)
Baricitinib R1—0/16 (0%)0/16 (0%)
Baricitinib T2—0/16 (0%)0/16 (0%)
Baricitinib R2—0/16 (0%)0/16 (0%)
Baricitinib T2F—0/16 (0%)0/16 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Overall Study
Mean36.8 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female0
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino0
Not Hispanic or Latino16
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native0
Asian16
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall Study
Japan16
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hachioji, Tokyo 192-0071, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2014
First posted
Oct 13, 2014
Start
Nov 2014
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Apr 21, 2017
Last update
Jun 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02263911
Responsible party
Sponsor
First posted
Oct 13, 2014
Start date
Nov 2014
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Apr 21, 2017
Last update
Jun 6, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion